Ingredient or product comparison
GHK-Cu Pharmacokinetics: Dosing Frequency Comparison
Plasma Trough Level Consistent. New dose before prior clearance Intermittent. 24–48h gap between doses Negligible. Peptide fully clears between doses Daily dosing maintains tissue-level receptor saturation; weekly dosing loses pharmacological continuity Tissue
This source-based comparison does not add ratings or recommend a winner.
- Plasma Trough Level
- Consistent. New dose before prior clearance
- Intermittent. 24–48h gap between doses
- Negligible. Peptide fully clears between doses
- Daily dosing maintains tissue-level receptor saturation; weekly dosing loses pharmacological continuity
- Tissue Collagen Response
- Sustained upregulation of COL1A1, COL3A1 genes
- Cyclical upregulation. Returns to baseline between doses
- Single transient spike. No sustained synthesis
- Gene expression requires repeated signalling; one pulse per week is insufficient
- VEGF Angiogenesis Signal
- Continuous low-level activation
- On-off cycling. May reduce net vessel formation
- Brief activation without follow-through
- Angiogenesis (new capillary formation) requires 3–5 days of sustained VEGF signal. Interrupted dosing aborts the process
- Wound Healing Progression
- Continuous phase progression (inflammation → proliferation → remodelling)
- Stalled progression. Healing phases require uninterrupted signalling
- Minimal effect. Single dose insufficient to complete any healing phase
- Wound repair is a multi-day process; intermittent GHK-Cu dosing creates gaps that delay or halt phase transitions
- Practical Compliance
- High adherence required. Daily injection discipline
- Moderate adherence. Easier to forget doses
- Low adherence risk. Single weekly event
- Daily protocols show better outcomes but demand consistent execution; weekly dosing is compliant but pharmacologically inadequate